Diabetes. 2012;61(5):1243-1249. Our studies underline several important parameters to take into consideration when designing studies to look for histological diagnosis of rare findings such as ...

Eli Lilly and its investors this past week learned a hard lesson: The sky is no longer the limit when it comes to sales of its blockbuster glucagon-like peptide 1 (GLP-1) drugs for diabetes and ...

Liraglutide is a GLP-1 analog, which is resistant to degradation. Phase III trials have demonstrated that liraglutide effectively controls glucose levels, while reducing bodyweight.

Several families of hormones can be used to achieve significant weight loss, starting with GLP-1 (e.g. semaglutide, tirzepatide), but also amylin analogs (e.g. cagrilintide, eloralintide, ...

Like other GLP-1 agonists, the most common side effects ... revealing that two other drug candidates—insulin analogs called GZR4 and GZR101—outperformed Novo's Tresiba (insulin degludec ...

Highly competitive, clinical-stage portfolio accelerating Phase 2 trials of ultra-long acting, fully-biased injectable GLP-1 RA underway Metsera recently ... Ultra-long acting amylin analog clinical ...

The authors stated (in lines between lines 78-83) a number of potential side effects of GLP-1 analogs, how can the mechanistic study of GLP-1 production on its own be essential for the development of ...

Aside from GLP-1 analogs, researchers also looked at the prescribing patterns of SGLT2 inhibitors—another popular class of T2D medication—and found similar trends. In 2010, 0.1% of T1D patients were ...